Eckhart Weidmann - Concepedia

Author

Eckhart Weidmann

Goethe University Frankfurt

Also Known As

E WEIDMANN, E Weidmann, E. Weidmann, Eckhart Weidmann, Weidmann, E

150

Publications

7.6K

Citations

H-Index

Concepts

All Affiliations

Goethe University Frankfurt Krankenhaus Nordwest University Hospital Frankfurt Klinikum Leverkusen Klinikum Lüdenscheid

About

Eckhart Weidmann is an author at Goethe University Frankfurt specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	46	3.9K
2	Health Sciences	6	6	1.9K
3	Engineering	1	1	34
4	Biochemistry	1	1	33
5	Biomedical Engineering	1	1	34

Eckhart Weidmann

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Mathias Rummel, N. Niederle, Georg Maschmeyer, The Lancet Lymphoid NeoplasiaRituximab Versus ChopOncologyMantle-cell LymphomasMetronomic Therapy	2013	1.5K
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707
High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome Lothar Bergmann, Cornelius Miething, Ulrich Maurer, Blood	1997	352
Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology Bernard Conrad, Eckhart Weidmann, Giuliana Trucco, Nature Metabolic SyndromeSuperantigen InvolvementDiabetesPhysiologyPathology	1994	311
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure Veronica Miller, Caroline Sabin, Kurt Hertogs, AIDS	2000	224
High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia T. Karakas, Ulrich Maurer, Eckhart Weidmann, Annals of Oncology Hematological MalignancyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaImmunology	1998	164
Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). Mathias Rummel, N. Niederle, Georg Maschmeyer, Blood	2009	157
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial Mathias Rummel, Ulrich Kaiser, Christina Balser, The Lancet Oncology Lymphoid NeoplasiaOncologyMantle-cell LymphomasPathologyRelapsed Indolent	2015	153
The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Jürgen Brieger, Eckhart Weidmann, Klaus Fenchel, PubMed	1994	116
The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Ulrich Maurer, Jürgen Brieger, Eckhart Weidmann, PubMed	1997	113

Page 1